Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Proacta initiates trial of anticancer treatment
Tumor hypoxia exists in the majority of solid tumors and can make treatment with conventional chemotherapy and radiation less likely to succeed. PR-104 is designed to be activated
Tumor hypoxia exists in the majority of solid tumors and can make treatment with conventional chemotherapy and radiation less likely to succeed. PR-104 is designed to be activated
The Japanese Ministry of Health has approved Gonal-f 75 IU and Gonal-f 150 IU (follitropin alfa recombinant) for co-administration with Profasi 5000 IU (chorionic gonadotropin) to help induce
This new class of compounds is expected to be comparable to opioids, the current gold standard in pain relief, in terms of efficacy, but not to possess the
The independent commission has given a positive recommendation based on evaluation of the data in the company’s current pivotal phase II trial of NX-1207 in benign prostatic hyperplasia
Antigen Express, Generex’s wholly owned subsidiary, will meet with the FDA in February to discuss requirements for the filing of an investigational new drug (IND) application for the
Syntonix is to be responsible for marketing in North America whilst Biovitrum is responsible for marketing in Europe, Russia and the Middle East. The companies will equally share
CytRx plans to provide all patients who complete the ongoing phase II trial with the opportunity for treatment with arimoclomol at the highest dose level three times daily
The company’s lead product candidate, alfimeprase, has received the designation for the treatment of acute peripheral arterial occlusion (PAO), or “leg attack.” Acute PAO occurs when arterial blood
The designation is granted to drugs that are for serious conditions that affect not more than five in ten thousand persons in the European Community, and where there
Can-Fite has had an open investigational new drug (IND) for rheumatoid arthritis (RA) in the US since early January. Under this open IND the company is currently conducting